NASDAQ: ICVXIcosavax Inc Stock
$7.75-0.05 (-0.64%)
Updated Sep 29, 2023
ICVX Price
$7.75
Fair Value Price
N/A
Market Cap
$387.86M
52 Week Low
$2.28
52 Week High
$16.45
P/E
-3.33x
P/B
1.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$96.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$67M
Beta
1.28
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ICVX Overview
Icosavax Incorporated is a biopharmaceutical company developing vaccines against infectious, life-threatening respiratory diseases. Icosavax was incorporated in 2017 and is headquartered in Seattle, WA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ICVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ICVX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ICVX is good value based on its book value relative to its share price (1.57x), compared to the US Biotechnology industry average (5.09x)
P/B vs Industry Valuation
ICVX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ICVX due diligence checks available for Premium users.
Be the first to know about important ICVX news, forecast changes, insider trades & much more!
ICVX News
Valuation
ICVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.33x
Industry
13.67x
Market
12.37x
ICVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.57x
Industry
5.09x
ICVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ICVX's financial health
Profit margin
Revenue
$0.0
Net Income
-$26.5M
Profit Margin
0%
ICVX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$269.0M
Liabilities
$21.3M
Debt to equity
0.09
ICVX's short-term assets ($251.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICVX's short-term assets ($251.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.2M
Investing
$55.8M
Financing
$68.1M
ICVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ICVX vs Biotech Stocks
Icosavax Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.